AP2618A - Aqueous suspensions of TMC278 - Google Patents

Aqueous suspensions of TMC278

Info

Publication number
AP2618A
AP2618A AP2008004682A AP2008004682A AP2618A AP 2618 A AP2618 A AP 2618A AP 2008004682 A AP2008004682 A AP 2008004682A AP 2008004682 A AP2008004682 A AP 2008004682A AP 2618 A AP2618 A AP 2618A
Authority
AP
ARIPO
Prior art keywords
tmc278
aqueous suspensions
suspensions
aqueous
Prior art date
Application number
AP2008004682A
Other languages
English (en)
Other versions
AP2008004682A0 (en
Inventor
Lieven Elvire Colette Baert
Willy Albert Maria Carlo Dries
Laurent Bruno Schueller
Original Assignee
Tibotec Pharmaceutical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38833797&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP2618(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tibotec Pharmaceutical Ltd filed Critical Tibotec Pharmaceutical Ltd
Publication of AP2008004682A0 publication Critical patent/AP2008004682A0/xx
Application granted granted Critical
Publication of AP2618A publication Critical patent/AP2618A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AP2008004682A 2006-06-23 2007-06-22 Aqueous suspensions of TMC278 AP2618A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06115938 2006-06-23
PCT/EP2007/056230 WO2007147882A2 (en) 2006-06-23 2007-06-22 Aqueous suspensions of tmc278

Publications (2)

Publication Number Publication Date
AP2008004682A0 AP2008004682A0 (en) 2008-12-31
AP2618A true AP2618A (en) 2013-03-18

Family

ID=38833797

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2008004682A AP2618A (en) 2006-06-23 2007-06-22 Aqueous suspensions of TMC278

Country Status (33)

Country Link
US (4) US20090176813A1 (es)
EP (2) EP3366278B1 (es)
JP (1) JP5292288B2 (es)
KR (1) KR101406879B1 (es)
CN (1) CN101478950B (es)
AP (1) AP2618A (es)
AR (1) AR061620A1 (es)
AU (1) AU2007262941B2 (es)
BR (2) BRPI0713334B1 (es)
CA (1) CA2654115C (es)
CL (1) CL2007001847A1 (es)
CY (1) CY1120564T1 (es)
DK (2) DK2040671T3 (es)
EA (1) EA021700B1 (es)
ES (1) ES2662068T3 (es)
FI (1) FI3366278T3 (es)
HR (1) HRP20180629T1 (es)
HU (1) HUE038797T2 (es)
IL (1) IL195491A (es)
JO (1) JOP20200160A1 (es)
LT (1) LT2040671T (es)
MX (1) MX2009000158A (es)
NZ (1) NZ573291A (es)
PE (1) PE20080210A1 (es)
PL (1) PL2040671T3 (es)
PT (1) PT2040671T (es)
RS (1) RS57111B1 (es)
SG (1) SG173315A1 (es)
SI (1) SI2040671T1 (es)
TW (1) TWI413521B (es)
UA (1) UA97641C2 (es)
UY (1) UY30431A1 (es)
WO (1) WO2007147882A2 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
TWI457136B (zh) * 2005-04-04 2014-10-21 Tibotec Pharm Ltd Ｈｉｖ-感染之預防
AR065720A1 (es) 2007-03-14 2009-06-24 Tibotec Pharm Ltd Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso.
EP2306980A2 (en) * 2008-06-30 2011-04-13 Tibotec Pharmaceuticals Powders for reconstitution
MY160360A (en) * 2008-12-24 2017-02-28 Janssen Sciences Ireland Uc Implantable devices for treating hiv
BR112013026363B1 (pt) * 2011-04-15 2021-10-13 Janssen Pharmaceutica Nv Nanossuspensões compreendendo 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]amino]-2-pirimidinil] amino] benzonitrila, seu processo de preparação e composição farmacêutica para administração por injeção intramuscular ou subcutânea
JO3387B1 (ar) 2011-12-16 2019-03-13 Glaxosmithkline Llc مشتقات بيتولين
SG10201704467SA (en) 2012-12-14 2017-06-29 Glaxosmithkline Llc Pharmaceutical compositions
JP2017528497A (ja) * 2014-09-26 2017-09-28 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ 長時間作用型医薬組成物
JP6704058B2 (ja) * 2016-05-31 2020-06-03 タイメド・バイオロジクス・インコーポレイテッドＴａｉＭｅｄ Ｂｉｏｌｏｇｉｃｓ Ｉｎｃ． プロテアーゼ阻害剤の長時間作用性医薬組成物
TWI678203B (zh) * 2016-05-31 2019-12-01 中裕新藥股份有限公司 蛋白酶抑制劑之長效醫藥組合物
US10369129B2 (en) * 2016-05-31 2019-08-06 Taimed Biologics, Inc. Long acting pharmaceutical composition of protease inhibitor
ES2970870T3 (es) 2016-10-24 2024-05-31 Janssen Sciences Ireland Unlimited Co Composiciones dispersables
RS65207B1 (sr) 2017-07-14 2024-03-29 Janssen Pharmaceutica Nv Formulacije bedakvilina sa dugim delovanjem
CN113440529B (zh) * 2020-03-25 2023-11-14 江苏恒瑞医药股份有限公司 一种可注射的药物组合物及其制备方法
JP2023532982A (ja) 2020-07-09 2023-08-01 ヤンセン ファーマシューティカ エヌ．ベー． 長時間作用型配合物
EP4178540A1 (en) 2020-07-09 2023-05-17 JANSSEN Pharmaceutica NV Long-acting formulations
WO2022008643A1 (en) 2020-07-09 2022-01-13 Janssen Pharmaceutica Nv Long-acting formulations
KR20230110763A (ko) * 2020-11-17 2023-07-25 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 질환 또는 장애의 치료 또는 예방
TW202233192A (zh) 2020-11-17 2022-09-01 愛爾蘭商健生科學愛爾蘭無限公司 Hiv感染之治療或預防
KR20240095514A (ko) 2021-11-17 2024-06-25 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 용해도 평가
TW202408516A (zh) 2022-04-22 2024-03-01 愛爾蘭商健生科學愛爾蘭無限公司 液體組成物
TW202408580A (zh) 2022-04-22 2024-03-01 愛爾蘭商健生科學愛爾蘭無限公司 冷凍乾燥組成物(二)
TW202408527A (zh) 2022-05-17 2024-03-01 愛爾蘭商健生科學愛爾蘭無限公司 治療或預防hiv感染(二)
WO2023222754A1 (en) 2022-05-17 2023-11-23 Janssen Sciences Ireland Unlimited Company Rilpivirine for use in the treatment or prevention of hiv infection
WO2024068693A1 (en) 2022-09-28 2024-04-04 Janssen Pharmaceutica Nv Long-acting formulations
WO2024068699A1 (en) 2022-09-28 2024-04-04 Janssen Pharmaceutica Nv Long-acting formulations

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221400B1 (en) * 1997-02-13 2001-04-24 Elan Pharma International Limited Methods of treating mammals using nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors
WO2003016306A1 (en) * 2001-08-13 2003-02-27 Janssen Pharmaceutica N.V. Hiv inhibiting pyrimidines derivatives
WO2006106103A2 (en) * 2005-04-04 2006-10-12 Tibotec Pharmaceuticals Ltd. Prevention of hiv- infection with tmc278
WO2007082922A2 (en) * 2006-01-20 2007-07-26 Tibotec Pharmaceuticals Ltd. Long term treatment of hiv- infection with tcm278

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4102124A (en) * 1976-07-12 1978-07-25 Swager William E Locking clevis or the like
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5046881A (en) * 1991-02-01 1991-09-10 Swager William E Lockable pin and clevis
US5114260A (en) * 1991-05-13 1992-05-19 Hart Judy L Clevis and screw pin type shackle with pin lock
US5272824A (en) * 1993-05-10 1993-12-28 Caterpillar Inc. Tooth assembly with leaf spring retainer
US5423138A (en) * 1994-04-04 1995-06-13 Caterpillar, Inc. Tip to adapter interface
UA72189C2 (uk) * 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
EP1214059B1 (en) * 1999-09-21 2005-05-25 Skyepharma Canada Inc. Surface modified particulate compositions of biologically active substances
US7638522B2 (en) 2001-08-13 2009-12-29 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
CA2465779A1 (en) * 2001-11-20 2003-05-30 Advanced Inhalation Research, Inc. Compositions for sustained action product delivery
US7101576B2 (en) * 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations
KR20130030305A (ko) * 2004-11-16 2013-03-26 엘란 파마 인터내셔널 리미티드 주사가능한 나노입자형 올란자핀 제형

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221400B1 (en) * 1997-02-13 2001-04-24 Elan Pharma International Limited Methods of treating mammals using nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors
WO2003016306A1 (en) * 2001-08-13 2003-02-27 Janssen Pharmaceutica N.V. Hiv inhibiting pyrimidines derivatives
WO2006106103A2 (en) * 2005-04-04 2006-10-12 Tibotec Pharmaceuticals Ltd. Prevention of hiv- infection with tmc278
WO2007082922A2 (en) * 2006-01-20 2007-07-26 Tibotec Pharmaceuticals Ltd. Long term treatment of hiv- infection with tcm278

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JANSSEN P A ET AL: "IN SEARCH OF A NOVEL ANTI-HIV DRUG: MULTIDISCIPLINARY COORDINATION IN THE DISCOVERY OF 4-[[4-[[4-[(1E)-2-CYANOETHENYL]-2,6-DIMETH YLPHENYL]AMINO]-2-PYRIMIDINYL]AMINO]BEBZON ITRILE (R278474, RILPIVIRINE)" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 48, no. 6, 6 November 2004 (2004-11-06), pages 1901-1909, XP008050052 ISSN: 0022-2623 *
LIVERSIDGE E M ET AL: "Nanosizing: a formulation approach for poorly-water-soluble compounds" EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, ELSEVIER, AMSTERDAM, NL, vol. 18, 2003, pages 113-120, XP002399359 ISSN: 0928-0987 *
MUELLER R H ET AL: "Nanosuspensions as particulate drug formulations in therapy: Rationale for development and what we can expect for the future" ADVANCED DRUG DELIVERY REVIEWS, AMSTERDAM, NL, vol. 47, no. 1, 2001, pages 3-19, XP002232883 ISSN: 0169-409X *
VAN EERDENBRUGH ET AL: "Characterization of physico-chemical properties and pharmaceutical performance of sucrose co-freeze-dried solid nanoparticulate powders of the anti-HIV agent loviride prepared by media milling" INTERNATIONAL JOURNAL OF PHARMACEUTICS, AMSTERDAM, NL, vol. 338, no. 1-2, 23 May 2007 (2007-05-23), pages 198-206, XP022093455 ISSN: 0378-5173 *

Also Published As

Publication number Publication date
ES2662068T3 (es) 2018-04-05
UY30431A1 (es) 2008-01-31
WO2007147882A2 (en) 2007-12-27
BR122020011487B1 (pt) 2024-02-20
FI3366278T3 (fi) 2024-09-25
SI2040671T1 (en) 2018-05-31
NZ573291A (en) 2011-11-25
IL195491A0 (en) 2009-09-01
AU2007262941A1 (en) 2007-12-27
JP5292288B2 (ja) 2013-09-18
US20220273653A1 (en) 2022-09-01
US20150010637A1 (en) 2015-01-08
RS57111B1 (sr) 2018-06-29
LT2040671T (lt) 2018-05-10
BRPI0713334A8 (pt) 2018-01-02
HUE038797T2 (hu) 2018-11-28
AU2007262941B2 (en) 2013-11-21
DK2040671T3 (en) 2018-05-07
EP3366278A1 (en) 2018-08-29
TW200817008A (en) 2008-04-16
HRP20180629T1 (hr) 2018-06-01
MX2009000158A (es) 2009-01-23
US20160089369A1 (en) 2016-03-31
SG173315A1 (en) 2011-08-29
JOP20200160A1 (ar) 2022-10-30
TWI413521B (zh) 2013-11-01
CL2007001847A1 (es) 2008-02-08
CN101478950A (zh) 2009-07-08
CN101478950B (zh) 2013-02-06
PE20080210A1 (es) 2008-04-11
CY1120564T1 (el) 2019-07-10
EA200970047A1 (ru) 2009-04-28
US20090176813A1 (en) 2009-07-09
US11389447B2 (en) 2022-07-19
UA97641C2 (en) 2012-03-12
WO2007147882A3 (en) 2008-06-19
JP2009541271A (ja) 2009-11-26
EP2040671A2 (en) 2009-04-01
EP3366278B1 (en) 2024-08-07
EP2040671B1 (en) 2018-01-24
EA021700B1 (ru) 2015-08-31
DK3366278T3 (da) 2024-09-23
PL2040671T3 (pl) 2018-08-31
KR101406879B1 (ko) 2014-06-13
KR20090023703A (ko) 2009-03-05
AP2008004682A0 (en) 2008-12-31
CA2654115C (en) 2015-12-22
PT2040671T (pt) 2018-03-14
CA2654115A1 (en) 2007-12-27
BRPI0713334B1 (pt) 2024-02-20
BRPI0713334A2 (pt) 2012-03-06
AR061620A1 (es) 2008-09-10
IL195491A (en) 2014-11-30

Similar Documents

Publication Publication Date Title
HRP20180629T1 (hr) Vodene suspenzije tmc278
AP2716A (en) Treatment of aqueous suspensions
AP2449A (en) Concentration of suspensions
EP2268777A4 (en) STABLE AQUEOUS EXCAVATIVE SUSPENSIONS
EP1982857A4 (en) SUSPENSION SPRING SEAT
AP2008004691A0 (en) Stable aqueous suspension
GB0724056D0 (en) Oxygenation of aqueous systems
EP1838906A4 (en) PREPARATION OF SUSPENSIONS
EG26602A (en) Water suspension formulation to exterminate pests
HK1161122A1 (en) Use of 24-norudca 24-norudca
GB0718696D0 (en) Treatment of an aqueous suspension of solid particles
GB0617290D0 (en) Suspension unit
IL191644A0 (en) Aqueous suspension concentrates
ZA200803880B (en) Aqueous suspension concentrates
ZA200807136B (en) Aqueous suspension concentrate
GB0607321D0 (en) Pivotless suspension
GB0610246D0 (en) Stable aqueous suspension
GB0610058D0 (en) Stable aqueous suspension
GB0615769D0 (en) Suspension
GB0703923D0 (en) Aqueous mica suspension
SE0602473L (sv) Upphängningsorgan
ES1064430Y (es) Nebulizador de suspensiones
HU0500461D0 (en) Pyperazinyl derivatives of alkyl-oxindoles
GB0523775D0 (en) Dispersions of inorganic particulates
GB0618112D0 (en) Lens suspension